Jci_page_head_homepage_01 Jci_page_head_homepage_02
Tanya Ponomaryov, Amnon Peled, Isabelle Petit, Russell S. Taichman, Liliana Habler, Judith Sandbank, Fernando Arenzana-Seisdedos, Aude Magerus, Antonio Caruz, Nobutaka Fujii, Arnon Nagler, Meir Lahav, Martin Szyper-Kravitz, Dov Zipori, Tsvee Lapidot
Published in Volume 106, Issue 11
J Clin Invest. 2000; 106(11):1331–1339 doi:10.1172/JCI10329
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

(a) Expression of SDF-1 and CXCR4 by RT-PCR. Lane a: endothelial MBA-2.1 cells; lane b, adipocyte 14F1.1 cells; lane c, osteoblast MBA-15 cells; lane d, HUVECs; lane e, primary human stroma. Expression of GAPDH and SDF-1: primary HOBs (lanes 1–4), osteosarcomas MG-63 (lane 5), and SaOS-2 (lane 6). (b) Migration of CD34+ cells to CM: SDF-1 migration to 125 ng/ml SDF-1, MBA-15, HOB3, HOB4, MG-63, 14F1.1, MBA-2.1, HUVECs. αCXCR4 or T22 pretreatment of CD34+ before Transwell migration. The results are the mean of seven different experiments ± SE. (c) Engraftment by CD34 cells migrating (M) and nonmigrating (NM) to MBA15 CM. Human CD45+CD19+ cells (R1) in the BM of mice transplanted with cells migrating to CM of MBA-15.